[1] G. Sportelli et al., First full-beam PET acquisitions The number of facilities that offer tumor treatment with particle therapy has been increasing substantially over the past decades. The dose distribution deposited by ions, and for the heaviest, their higher biological effectiveness, make them more interesting to destroy localized tumors while sparing healthy tissues. Such an effectiveness is quantified through the RBE (relative biological effectiveness), which is a complex function of multiple parameters like cell line, cell cycle stage, radiation quality and irradiation conditions. Therefore, determining the value of RBE for every scenario is a challenging task that requires modeling to comply with the demands of a clinical environment. Several solutions have already been developed and a few are currently used in treatment planning [1] [2] [3] [4] . Nevertheless, despite the progress these models have allowed, they present some shortcomings [5] [6] [7] that may limit their improvement. We present thereby a new approach that gathers some principles of the existing ones and addresses some of their weaknesses. The innovative features of Nanox TM are that it is fully based on statistical physics, taking in particular into account the fluctuations in energy deposition at multiple scales, and that it introduces the concept of a chemical dose. The latter is chosen as a parameter defined at the cell scale to represent the induction of cell death by "non-local" events as the accumulation of cellular oxidative stress or sublethal lesions induced by the produced radical species. Such "non-local" events are complementary to the so-called "local" events, which take place at a very localized (nanometric) scale. The "local" events are considered as lethal since a single event can cause cell death. The cell survival predicted by Nanox TM for V79 cell line was compared with experimental results for photons, protons and carbon ions, and even others like neon and argon ions. A good agreement was found in all cases. In particular, the model is able to describe the effectiveness of ions, including the overkill effect at higher LET values. Moreover, Nanox TM can reproduce the typical shoulder in cell survival curves. This was possible due to the introduction of the "non-local" events, through the chemical dose, which varies with LET. It is worthwhile to note that such results were obtained through the adjustment of a reduced number of free parameters. The first results of Nanox TM , obtained for V79 cell line, give us confidence that this model has potential for application in a clinical scenario in the context of particle therapy. Although it requires the tuning of only a few free parameters, Nanox TM is based on solid principles and a thorough mathematical implementation, which renders this approach simple but reliable for application in clinical practice.
Keywords: RBE; multiscale dosimetry; oxidative stress Purpose: The advent of personalized medicine in radiotherapy (RT) is accompanied by the need for accurate outcome prediction. The current state of predictions made by physicians for patient survival and toxicity after lung radiotherapy is comparable to flipping a coin (Oberije et al.,Radiother. Oncol. 2014) . In order to assess the value of expert knowledge in prediction modelling (rather than directly predicting outcomes), expert-based and data-driven prediction models were built and compared. Models for two endpoints were created: 2-year survival in NSCLC non-surgery patients and severe dyspnea (CTCAE dyspnea scores ≥ 2) after RT. Materials/methods: Data from lung cancer patients (994 for dyspnea, 452 for 2-year survival) treated in clinical routine were collected. 10 experts (4 experts participated for both endpoints) selected causal links between patient, disease, treatment, and dose-related variables (19 for dyspnea, 17 for 2-year survival) and the two outcomes. The selected links were used to construct Bayesian Networks (BN) for a comparison with BNs based on a data-driven algorithm. These models were then learned on 80% and validated on 20% of the patient data. Discrimination in the validation data sets is assessed by the Area under the Curve (AUC).
